Amlodipine vs Amlodipine and Olmesartan Medoxomil — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Dihydropyridine Calcium Channel Blocker

Amlodipine

Brand: Katerzia

First FDA approval: 1992-07-31

Dihydropyridine Calcium Channel Blocker

Amlodipine and Olmesartan Medoxomil

Brand: Azor

First FDA approval: 2007-09-26

Lowest NADACAcquisition cost floor across all NDCs

$0.011Per unit

$0.240Per unit

Average NADACAcross all dosage forms and strengths

$0.906Up to $11.86

$1.29Up to $17.87

Generic manufacturersActive ANDA holders — FDA Orange Book

1960 total ANDAs filed

936 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$515.5MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

75.9M23.4M beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$7Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

6Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes19 manufacturers

Yes9 manufacturers